Antiphospholipid Antibody Syndrome. Rare Diseases of the Immune System

1. Genetics and Origin of Antiphospholipid Syndrome

Alessandra Soriano1, 2  , Miri Blank  and Yehuda Shoenfeld1, 4  

(1)

Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center – Affiliated to Tel Aviv University, Tel Hashomer, 52621, Israel

(2)

Department of Clinical Medicine and Rheumatology, Campus Bio-Medico University, Rome, 00128, Italy

(3)

Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center – Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer, 52621, Israel

(4)

Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel Hashomer, 52621, Israel

Alessandra Soriano

Email: soriano.alessandra@gmail.com

Miri Blank

Email: Miri.Blank@sheba.health.gov.il

Yehuda Shoenfeld (Corresponding author)

Email: Yehuda.Shoenfeld@sheba.health.gov.il

1.1 Introduction

Antiphospholipid syndrome (APS) is a multisystemic autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity associated with the concomitant detection of antiphospholipid antibodies (aPL), including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-β2 glycoprotein I (anti-β2GPI) antibodies [1].

Actually, aPL are a heterogenous group of antibodies that react with a myriad of phospholipids (PLs), PL-protein complexes, and PL-binding proteins. The main antigenic target of these antibodies is recognized to be β2GPI, which along with prothrombin accounts for more than 90 % of the antibody-binding activity in APS patients [24].

The genetic basis of aPL [5] and APS [6] has been suggested by several authors according to many clinical evidences, family studies, and experimental models, although the underlying genetic factors predisposing to APS have not been clearly established. Future research in this field may help in delineating also the mechanisms for APS [7].

Similarly, the origin of pathogenic aPL remains to be clearly elucidated. Several environmental factors have been studied in the last decades, with most of the evidence regarding a wide spectrum of infectious agents, which could be responsible for the “second hit” in the APS pathophysiological mechanisms. Molecular mimicry, epitope spreading, and bystander activation are some of the proposed mechanisms through which infectious agents may act in an individual with a procoagulant phenotype, the latter defined as the “first hit” [8].

The focus of this chapter is to gather the most recent scientific evidence with regard to genetics and origin of APS.

1.2 Genetics in APS: Family, Population, and Genome-Wide Association Studies

The human leukocyte antigen (HLA) association with aPL and APS has been studied through various animal models, family and population studies, and more recently, through genome-wide association studies (GWAS). It has emerged that both autoantibody production and disease expression may be influenced by major histocompatibility complex (MHC) genes [8]. In addition, prothrombotic genetic markers may modify the disease expression in APS patients especially when associated with acquired factors such as aPL [9].

APL are a heterogeneous group of antibodies with many different antigenic targets. Today we know that only a limited number of aPL are pathogenic, being induced in most of the cases by certain viral or bacterial products and determining a break in tolerance because of sequence similarities with host antigens [1011].

Nevertheless, nowadays it is also clear that a favorable genetic background is essential for the subsequent development of APS, similarly to other autoimmune diseases.

In 1966, Harvey and Shulman [12] described the first family with persistent false-positive tests for syphilis detected in their members, in whom a full-blown autoimmune disease developed years later. In the following decades, several studies described families with high incidence of primary APS associated with LA, aCL, and other autoantibodies [61314].

A link with HLA haplotypes has been reported in different family studies on APS: the paternal haplotypes A30, Cw3, B60, DR4, DRw53, and DQw3 have been shown in association with aCL in all the members of an English Canadian family, both in asymptomatic individuals and in those affected with APS secondary to systemic lupus erythematosus (SLE) and autoimmune thyroid disease. In addition, the presence of LA has been demonstrated in family members carrying DR4 and DR7 [1516].

A dominant or codominant model for inheritance of the disease by segregation analysis was suggested in a 1998 study considering seven families with a high incidence of primary APS, among which 30 out of 101 members met the diagnostic criteria. However, the study failed to find a linkage to HLA nor to other candidate genes including β2-GPI and Fas [17].

Apart from family studies, association of HLA and APS has been demonstrated in cohorts of patients with primary APS, in which DRB1*04, DR7, DQB1*0301/4, DQB1*0604/5/6/7/8/9, DQA1*0102, and DQA1*0301/2 were found with increased frequency [1820]. The analysis of a large series of European patients with SLE by Galeazzi et al. [21] has found an association of aCL with HLA-DRB1*04, −DRB1*07, DQA1*0201, DQA1*0301, DQB1*0301, DQB1*0302, and DRB3*0301, while anti-β2GPI were positively associated with DQB1*0302.

Furthermore, the detection of anti-β2GPI was strongly associated with DRB1*1302 and DQB1*0604/0605 haplotypes in African American and in white British patients with primary APS [1822], while in Caucasian and Mexican Americans, DQB1*0302 was strongly correlated with anti-β2GPI [182223].

Prothrombotic genetic factors have been found playing a role in modifying the disease expression in APS, namely, factor V Leiden mutation; antithrombin III, protein C, and protein S deficiencies; and prothrombin mutations [24]. Subjects with APS carrying factor V Leiden mutation showed an increased incidence of thrombosis in comparison to those without the mutation. On the other hand, other studies comparing the rates of thrombosis in APS patients with factor V Leiden mutation and in the general population (in which the frequency of factor V Leiden mutation ranges from 1 to 15 % for Caucasians) failed to detect a strong influence in APS population on the development of the thrombotic event [2426]. Moreover, there have been reports of increased risk of thrombosis in APS in case of protein C and S deficiency, as well as in case of association with G20210A mutation [27].

Tissue factor pathway inhibitor [28], type I plasminogen activator inhibitor [29], annexin A5 [30], and p-selectin glycoprotein ligand 21 [31] may potentially positively influence the risk of thrombosis in APS patients.

Recently, Pierangeli et al. [32] showed the in vivo pathogenic role of toll-like receptor 4 (TLR-4) in APS by studying the thrombogenic aPL activity in lipopolysaccharide (LPS) non-responsive (LPS −/−) mice and the association between tlr4 gene polymorphisms and APS in patients affected. The authors found significantly smaller thrombi and fewer white blood cells (WBC) count adhering to endothelial cells in LPS −/− mice displaying a tlr4 spontaneous mutation, when immunized with IgG from patient with APS, suggesting a potential role of TLR-4 in the interaction between aPL and endothelial cells in vivo.

Genome-wide association studies (GWAS) are a relatively new search method based on the study of several single nucleotide polymorphisms (SNPs) in order to identify those occurring more frequently in people affected with a certain disease. This type of study is generally used to pinpoint genes that may contribute to a subject’s risk of developing the disease.

Before the GWAS approach, SNPs analyses had been performed to investigate the genetic association between primary APS and SLE, given their clinical and serological similarities.

In 2009, 10 SNPs previously shown to be associated with SLE have been genotyped in a cohort of Italian APS patients [53]. The rationale of the study was to investigate whether the analysis of SLE susceptibility genes could partially provide an explanation for the small percentage of primary APS patients developing a full-blown SLE over the years, despite the similarities between the two conditions.

The study showed a very strong association with STAT4 and BLK SNPs; conversely, no association was detected with BANK1 [53]. These results were further confirmed when the authors extended their investigation through an additional group of APS patients [54].

Interestingly, in this further study a stronger association with one SNP of IRF5 (rs2070197), which is a tag for risk haplotype in SLE, was found in the additional group [54]. On the other hand, the lack of association with rs2004640, the strongest IRF5 SNP associated with SLE, was also confirmed. These last findings underlined that the differences in the genetic effects of IRF5 between APS and SLE may also account for some of their different clinical expressions.

A genome-wide association study recently performed in an effort to detect loci/genes for aCL, anti-β2GPI, and LA in a cohort of women of European ancestry affected with SLE and carriers of aPL identified a number of suggestive novel loci for aPL, including genes not located near or at the MHC locus [7].

Although the study did not identify loci meeting the conservative threshold of genome-wide significance, it has suggested the potential role in APS of other genes involved in the immune response, like SESTD1 and TANK, which play a role in binding PL species and in type I interferon production, respectively [7]. Undoubtedly, GWAS will contribute to open the way through new directions in the comprehension of APS genetics in the next future.

1.2.1 Genetic Animal Studies

Despite the fact that the first animal models on APS date back to 1980s [3334] – before the definition of APS – after three decades animal studies assessing the genetic basis for the development of this syndrome remain few.

The role of certain class of haplotypes in the production of pathogenic aPL came first from a study of Papalardo et al. [35] who elegantly showed the influence of MHC-II and the expression of DQ6, DQ8, and DR4 on the production of pathogenic aPL in mice. MHC-II deficient (−/−), DQ6, DQ8, and DR4 mice, MHC-II-deficient-transgenic mice, or their corresponding wild type (WT) were immunized with human β2GPI or with control protein ovalbumin. WT mice immunized with β2GPI produced significantly higher titers of aCL and anti-β2GPI when compared to controls, and this finding correlated with enhanced thrombus formation and tissue factor activity. MHC (−/−) mice immunized with β2GPI did not produce aCL or anti-β2GPI; mean thrombus sizes and tissue factor activities were significantly diminished, when compared to WT animals. Finally, the pathogenicity of aPL was fully reestablished in MHC (−/−) mice expressing DR4 and DQ8 haplotypes and partially restored in those expressing human DQ6 [35].

In 1992, Hashimoto et al. [36] in their model of APS demonstrated the spontaneous production of IgG aCL antibodies exhibiting the β2GPI-dependent binding to cardiolipin in NZW x BXSB F1 (W/B F1) male mice. Subsequent studies showed a preferential usage of certain VH and VK genes for the production of pathogenic aCL, while random V gene combinations were used for the production of nonpathogenic aCL, suggesting the possible antigen-driven mechanisms.

The search for triggering antigens was proved only in 1992, when Gharavi et al. [37] immunized NIH/Swiss mice with heterologous β2GPI rather than pure PLs, obtaining high-titer production of pathogenic aPL. These results were pivotal to orient research through the concept that the formation of immunogenic complexes against which aPL may be produced may occur when foreign PL-binding proteins with structures similar to β2-GPI bind to self PLs in vivo [8].

Several efforts have then been made in inducing high-titer production of pathogenic aPL in animal models, mainly through the immunization with peptides from microorganisms with functional and sequence similarity to that of the PL-binding site of β2GPI. These studies also contributed to elucidate the origin of pathogenic aPL, as resumed in the following paragraph.

1.3 Infections and Innate Immunity Mechanisms

Apart from the complex aspects of the genetics of APS, the ontogeny itself of the pathogenic aPL remains poorly understood.

As underlined in the introduction to this chapter, despite the presence of an induced procoagulant phenotype which may be genetically determined and finally defines the so-called first hit, an additional inciting factor, namely, “second hit,” is necessary for the clinical manifestations of the disease [8].

Currently, infections are considered one of the most relevant environmental factors responsible for both aPL production and APS development.

The first infection recognized to be linked to aPL production was syphilis, although it was first hypothesized that syphilis-linked aPL were nonpathogenic [3840].

In the following decades, several reports then showed a link between different types of infections and the development of aPL, as well as clinical manifestations of APS. Namely, human immunodeficiency virus (HIV), human T-cell lymphoma/leukemia virus (HTLV), hepatitis B and C virus, varicella-zoster virus (VZV), parvovirus B19, and cytomegalovirus (CMV) have been associated with the production of aPL and the development of clinical manifestations of APS.

Later on, it was clearly postulated that incidental exposure of genetically susceptible individuals to certain infectious agents that bear β2GPI-like structures can induce a break in tolerance to this antigen, thus facilitating the production of pathogenic aPL [8]. In this regard, molecular mimicry has been proposed as one of the pivotal mechanisms for the production of pathogenic aPL, because of the breakdown in the normal mechanisms of peripheral tolerance.

Great part of the efforts in inducing high-titer production of pathogenic aPL in animal models have been made through the immunization with peptides from microorganisms with functional and sequence similarity to that of the PL-binding site of β2GPI [41].

Greater degrees of PL-binding were shown by the peptides TADL from adenovirus (AdV), TIFI and VITT from cytomegalovirus (CMV), and SGDF from Bacillus subtilis, all of them inducing both high-titer aPL and anti-β2GPI production in mice. The pathogenicity of the antibodies induced in TIFI-immunized mice was then confirmed in subsequent experiments in vitro and in vivo [4143].

Blank et al. [4445] added further evidence for a plausible role of molecular mimicry for the infectious origin of aPL: a β2GPI-related hexapeptide, TLRVYK, was identified by anti-β2GPI monoclonal antibodies originated from a patient with recurrent fetal loss on APS peptide background and peptide phage-displayed library. High titers of aCL β2GPI-dependent antibodies were produced through naïve mice immunization with 7 pathogens out of 24 showing high homology to TLRVYK. When purified anti-TLRVYK antibodies were passively transferred to naïve female mice, clinical manifestations of experimental APS were caused only by the autoantibodies originated from Haemophilus influenzae, Neisseria gonorrhoeae, or tetanus toxoid immunized mice, with high affinity to β2GPI.

The use of three synthetic peptides (namely, “A,” NTLKTPRVGGC; “B,” KDKATFGCHDGC; “C,” CATLRVYKGG) derived from a peptide phage-displayed library and reacting specifically with the anti-β2GPI monoclonal antibodies (mAbs) ILA-1, ILA-3, and H-3 has been shown to neutralize the pathogenic functional activity of anti-β2GPI mAbs in vitro [44]. In vivo infusion of each of the anti-β2GPI mAbs into BALB/c mice, followed by administration of the corresponding specific peptides, was able to prevent the peptide-treated mice from developing experimental APS [44].

Moreover, the synthetic peptide named peptide “A” NTLKTPRVGGC that shares similarity with common bacterial antigens prevented induction of thrombosis ex vivo in an aPL-mediated thrombosis [46]. Peptide “A” is also found in region I/II of β2GPI. A scrambled form of peptide “A” (scGTKGCPNVRLT) was used as a control and had no effect.

Evidence that LPS primes the endothelium of rat mesenteric vessels has been provided for anti-β2GPI-mediated thrombosis [55].

Additionally, treatment of mice with intraperitoneal injection of LPS following the injection of cyanine 5.5-labeled β2GPI has been shown to promote protein localization on gut and brain endothelial cells associated with IgG, C1q, and C9 deposition in immunized mice [56].

In this regard, a critical role for complement in inducing aPL-mediated blood clots and fetal resorption has been found first by using aPL of undefined specificity [55] and, afterward, by using specific antibodies to β2GPI [56]. Agostinis et al. [57] recently proposed a novel therapeutic approach based on the use of a high-affinity human monoclonal antibody to β2GPI that competes with the APS patients’ antibodies for binding to β2GPI and inhibits their ability to induce blood clots and fetal loss by determining the failure of complement activation [57].

As concerns the intracellular molecular pathways involved in β2GPI-dependent aPL-mediated endothelial cells activation and leading to procoagulating state of the cells, Meroni et al. [47] showed the role of TLR-4 as a co-receptor for MyD88 upregulation with the subsequent NFκB activation. This molecular pathway is specific for LPS-triggered innate immunity. In addition, as previously underlined, Pierangeli et al. [32] studied in vivo the pathogenic role of TLR-4 through evaluating the aPL activity in LPS non-responsive (LPS −/−) mice. It was shown that smaller thrombi developed in LPS −/− mice in comparison to LPS +/+ mice.

Three main plausible mechanisms have been proposed in order to explain the enhanced aPL production in the presence of LPS: (1) the interaction of T cells with antigen-presenting cells (APC) due to overexpression of co-stimulatory molecules induced by LPS, (2) the activation of APC and the subsequent production of TNF-α, and (3) the bystander activation of B cells [4849].

Recently, the role of LPS in the in vitro interaction of β2GPI with endothelial TLR-4 has been investigated by Raschi et al. [58]. In their model, the authors demonstrated a threshold effect for the action of LPS on endothelial cells, different from what was observed on monocyte/macrophages cultures.

Indeed, LPS has been found to enhance anti-β2GPI antibody endothelial cells binding only at cell-activating concentrations, shown to increase TLR-4 expression. Thereby, it has been speculated that LPS may act as an inflammatory stimulus upregulating TLR-4 expression and at the same time favoring the formation of β2GPI/LPS complexes. The interaction of β2GPI with TLR-4 – directly or complexed with LPS – can finally increase the presence of β2GPI on the endothelial cell surface, eventually allowing antibody binding, complement fixation, and clotting.

A similar cascade of events could explain the in vivo LPS effect in animal models [56] and can be hypothesized in vivo in APS patients who experienced some types of infectious processes that may represent trigger hits for clotting [5859].

Moreover, infectious agents could potentially induce autoimmune response through the selection (or destruction) of specific lymphocyte subsets, by releasing specific subsets of chemokines and cytokines, or by the exposure of cryptic autoantigens that can follow the cell necrosis and apoptosis.

The concept that cell damage could be one of the origins of aPL was first formulated by Piroux et al. [50] in 1997, who provided evidence about the peculiar recognition of surface epitopes – including β2GPI and anionic phospholipid complexes like phosphatidylserine (PS) – that are exposed following the cell apoptosis.

The binding of β2GPI to the surface of apoptotic cells was shown to generate an epitope recognized by aPL in patients affected with primary APS and SLE by Levine et al. [51].

Long-lasting circulating apoptotic cells presenting PS on the apoptotic blebs may lead to presentation of hidden epitopes or neo-epitopes of β2GPI once the complex PS/β2GPI has been constituted, finally triggering the immune response to self and inducing the production of aPL, including anti-β2GPI antibodies.

Similarly, it has been recently investigated the role of bacterial proteins in determining β2GPI conformational changes with following exposure of cryptic epitopes.

In particular, conformational changes in β2GPI have been hypothesized to trigger the formation of antibodies against a cryptic epitope in domain I of β2GPI, after its exposure on the outside of the molecule. Autoantibodies against the domain I of β2GPI have been found to be strongly associated with thrombotic events in APS patients and still represent a matter of extensive investigations [60].

Starting from these assumptions and given the previous evidence that β2GPI interacts with Streptococcus pyogenes [61], van Os et al. [62] recently injected mice with Streptococcus pyogenes-derived surface proteins, including M1 protein, protein H, streptococcal collagen-like protein A [SclA], and streptococcal collagen-like protein B [SclB].

They showed that the interaction of streptococcal protein H with plasma-derived β2GPI resulted in a conformational change in β2GPI, namely, from the plasmatic circular conformation through the fishhook shape, the latter being adopted after binding to phospholipids [62]. Anti-murine β2GPI IgM and IgG were detected only in mice challenged with multiple boosts of protein H (and not with boosts of the three other streptococcal proteins) and were mainly directed against domain I of β2GPI.

In their model, the authors hypothesized that during a long-lasting infection and probably following repetitive interactions between β2GPI and streptococcal protein H, the fishhook conformation of β2GPI triggers the immune system, resulting in the development of antibodies against the cryptic epitope in domain I of β2GPI. They finally speculated that proteins present on other microorganism may also bind to β2GPI and induce such a conformational change [62].

1.4 Other Potential Environmental Triggers Inducing the Production of aPL

Among other potential environmental triggers involved in the production of aPL, both solid and hematological malignancies have been reported in association with aPL and secondary APS, although the mechanisms remain to be elucidated. High levels of VEGF in patients affected with malignancies might contribute to tissue factor generation and procoagulant status in APS patients. The inflammatory network induced by the tumor cells, together with the pharmacological effects of chemotherapeutic drugs, could result in an increased amount of apoptotic cells which, as discussed above, are a further source of aPL and contribute to the development of thrombosis and also of catastrophic form of APS.

Several drugs including antiepileptic agents, antiarrhythmic drugs (procainamide), antipsychotic drugs such as chlorpromazine, antibiotics such as amoxicillin, and oral contraceptive drugs have been linked to increased titers of aPL, although data about prevalence of drug-induced aPL in APS are still lacking.

Furthermore, the exposure to acrylamide has been associated with the development of high levels of aCL and anti-β2GPI.

Finally, postvaccination-induced aPL following tetanus toxoid vaccine, hepatitis B vaccine, and influenza vaccine have been described in rare cases in association with APS clinical manifestations, but the pathophysiological mechanisms remain to be clarified [52].

References

1.

Meroni PL, Borghi MO, Raschi E et al (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7:330–339PubMedCrossRef

2.

McNeil HP, Simpson RJ, Cherterman CN et al (1990) Antiphospholipid antibodies are directed against a complex antigen that includes lipid binding inhibitor of coagulation: β2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87:4120–4124PubMedCentralPubMedCrossRef

3.

Galli M, Comfurius P, Maassen C et al (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544–1547PubMedCrossRef

4.

Amengual O, Atsumi T, Koike T (2004) Antiprothrombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immunol 112:144–149PubMedCrossRef

5.

Mackworth-Young C, Chan J, Harris N (1987) High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheumatol 14:723–726PubMed

6.

Matthey F, Walshe K, Mackie IJ et al (1989) Familial occurrence of the antiphospholipid syndrome. J Clin Pathol 42:495–497PubMedCentralPubMedCrossRef

7.

Ilyas Kamboh M, Wang X, Kao HA et al (2013) Genome wide association study for antiphospholipid antibodies. Autoimmune Dis 2013:761046

8.

Willis R, Nigel Harris E, Pierangeli SS (2012) Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 38:305–321PubMedCrossRef

9.

Castro-Marrero J, Balada E, Vilardell-Tarrés M et al (2009) Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br J Haematol 147:289–296PubMedCrossRef

10.

Gharavi AE, Pierangeli SS, Harris EN (2001) Origin of antiphospholipid antibodies. Rheum Dis Clin North Am 27:551–563PubMedCrossRef

11.

Gharavi AE, Pierangeli SS, Harris EN (2003) Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology 207:37–42PubMedCrossRef

12.

Harvey AM, Shulman LE (1966) Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction). Med Clin North Am 50:1271–1279PubMed

13.

Exner T, Barber S, Kronenberg H et al (1980) Familial association of the lupus anticoagulant. Br J Haematol 45:89–96PubMedCrossRef

14.

Jolidon RM, Knecht H, Humair L et al (1991) Different clinical presentations of a lupus anticoagulant in the same family. Klin Wochenschr 69:340–344PubMedCrossRef

15.

Rouget JP, Goudemand J, Montreuil G et al (1982) Lupus anticoagulant: a familial observation. Lancet 2(8289):105PubMedCrossRef

16.

Mackie IJ, Colaco CB, Machin SJ (1987) Familial lupus anticoagulants. Br J Haematol 67:359–363PubMedCrossRef

17.

Goel N, Ortel TL, Bali D et al (1999) Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum 42:318–327PubMedCrossRef

18.

Caliz R, Atsumi T, Kondeatis E et al (2001) HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford) 40:31–36CrossRef

19.

Bertolaccini ML, Atsumi T, Caliz AR et al (2000) Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 43:683–688

20.

Vargas-Alarcon G, Granados J, Bekker C et al (1995) Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. Arthritis Rheum 38:1340–1341PubMedCrossRef

21.

Galeazzi M, Sebastiani GD, Tincani A et al (2000) HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 9:47–55PubMedCrossRef

22.

Arnett FC, Thiagarajan P, Ahn C et al (1999) Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 42:268–274PubMedCrossRef

23.

Reverter JC, Tassies MD (2009) Genetic aspects of the antiphospholipid syndrome: associations with clinical manifestations. In: Handbook of systemic autoimmune diseases. Antiphospholipid syndrome in systemic autoimmune diseases. (Ed. by R. Cervera, J.C. Reverter and M. Khamashta). 10:91–103.

24.

Schütt M, Klüter H, Hagedorn-Greiwe M et al (1998) Familial coexistence of primary antiphospholipid syndrome and factor V Leiden. Lupus 7:176–182PubMedCrossRef

25.

Brenner B, Vulfsons SL, Lanir N et al (1996) Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 94:166–167PubMedCrossRef

26.

Chopra N, Koren S, Greer WL et al (2002) Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 29:1683–1688PubMed

27.

Ames PR, Margaglione M, Tommasino C et al (2001) Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 12:699–704PubMedCrossRef

28.

Lincz LF, Adams MJ, Scorgie FE et al (2007) Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. Blood Coagul Fibrinolysis 18:559–564PubMedCrossRef

29.

Yasuda S, Tsutsumi A, Atsumi T et al (2002) Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol 29:1192–1197PubMed

30.

de Laat B, Derksen RH, Mackie IJ et al (2006) Annexin A5 polymorphism (−1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 65:1468–1472

31.

Bugert P, Pabinger I, Stamer K et al (2007) The risk of thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. Thromb Haemost 97:573–580PubMed

32.

Pierangeli SS, Vega-Ostertag ME, Raschi E et al (2007) Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 66:1327–1333PubMedCentralPubMedCrossRef

33.

Hang LM, Izui S, Dixon FJ (1981) (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 154:216–221PubMedCrossRef

34.

Oyaizu N, Yasumizu R, Miyama-Inaba M et al (1988) (NZW x BXSB) F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med 167:2017–2022PubMedCrossRef

35.

Papalardo E, Romay-Penabad Z, Christadoss P et al (2010) Induction of pathogenic antiphospholipid antibodies in vivo are dependent on expression of MCH-II genes. Lupus 19:496CrossRef

36.

Hashimoto Y, Kawamura M, Ichikawa K et al (1992) Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 149:1063–1068PubMed

37.

Gharavi AE, Sammaritano LR, Wen J et al (1992) Induction of antiphospholipid antibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 90:1105–1109PubMedCentralPubMedCrossRef

38.

Wasserman A (1907) Über Entwicklung und den Gegenwartingen Stand der Serodiagnostic gegenüber Syphilis. Berl Klin Wochenschr 44:1599–1634

39.

Harris EN, Gharavi AE, Boey ML et al (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211–1214PubMedCrossRef

40.

Levy Y, Almog O, Gorshtein A et al (2006) The environment and antiphospholipid syndrome. Lupus 15:784–790PubMedCrossRef

41.

Gharavi EE, Chaimovich H, Cucurull E et al (1999) Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 8:449–455PubMedCrossRef

42.

Gharavi AE, Pierangeli SS, Espinola RG et al (2002) Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 46:545–552PubMedCrossRef

43.

Gharavi AE, Vega-Ostertag M, Espinola RG et al (2004) Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus 13:17–23PubMedCrossRef

44.

Blank M, Shoenfeld Y, Cabilly S et al (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci 96:5164–5168PubMedCentralPubMedCrossRef

45.

Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y (2002) Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 109:797–804PubMedCentralPubMedCrossRef

46.

Pierangeli SS, Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, Roye-Green K, Harris EN, Shoenfeld Y (2004) A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun 22:217–225PubMedCrossRef

47.

Meroni PL, Raschi E, Testoni C, Parisio A, Borghi MO (2004) Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 3:510–515PubMedCrossRef

48.

Benson MJ, Elgueta R, Schpero W et al (2009) Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med 206:2013–2025PubMedCentralPubMedCrossRef

49.

Khoruts A, Mondino A, Pape KA et al (1998) A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 187:225–236PubMedCentralPubMedCrossRef

50.

Piroux V, Eschwege V, Freyssinet JM (1997) Cell damage at the origin of antiphospholipid antibodies and their pathogenic potential in recurrent pregnancy loss. Infect Dis Obstet Gynecol 5:176–180PubMedCentralPubMedCrossRef

51.

Levine JS, Koh JS, Subang R et al (1999) Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp Mol Pathol 66:82–98PubMedCrossRef

52.

Blank M, Israeli E, Shoenfeld Y (2012) When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants. Lupus 21:711–714PubMedCrossRef

53.

Yin H, Borghi MO, Delgado-Vega AM, Tincani A, Meroni PL, Alarcon-Riquelme ME (2009) Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 60:2468–2471PubMedCrossRef

54.

Fredi M, Tincani A, Yin H, Delgado-Vega AM, Borghi MO, Meroni PL, Alarcon-Riquelme ME (2010) IRF5 is associated with antiphospholipid syndrome but is not a major risk factor. Arthritis Rheum 62:1201–1202PubMedCrossRef

55.

Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni PL, Tedesco F (2005) Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:2340–2346PubMedCrossRef

56.

Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, Bulla R, Grossi C, Borghi MO, Meroni PL, Tedesco F (2011) In vivo distribution of β2-glycoprotein I under various pathophysiologic conditions. Blood 118:4231–4238PubMedCrossRef

57.

Agostinis C, Durigutto P, Sblattero D, Borghi MO, Grossi C, Giuda F, Bulla R, Macor P, Pregnolato F, Meroni PL, Tedesco F (2014) A non-complement fixing antibody to β2-glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123:3478–3487PubMedCrossRef

58.

Raschi E, Chighizola C, Grossi C, Ronda N, Gatti R, Meroni PL, Borghi MO (2014) β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun Mar 27 [Epub ahead of print]

59.

Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL (2006) Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65:2–6PubMedCentralPubMedCrossRef

60.

de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF, Maas C (2011) Immune responses against domain I of β2-glycoprotein I are driven by conformational changes. Arthritis Rheum 63:3960–3968PubMedCrossRef

61.

Nilsson M, Wasylik S, Morgelin M, Olin AI, Meijers JC, Derksen RH, de Groot PG, Herwald H (2008) The antibacterial activity of peptides derived from human β2-glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 67:482–492PubMedCrossRef

62.

van Os GM, Meijers JC, Agar C, Seron MV, Marquart JA, Akesson P, Urbanus RT, Derksen RH, Herwald H, Morgelin M, de Groot PG (2011) Induction of anti β2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 9:2447–2456PubMedCrossRef


Previous
Page
Next
Page